Renin-angiotensin system (RAS) blockade by angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers is now regarded as one of the pivotal treatment modalities for cardiovascular diseases (CVDs), indicating that the RAS plays a critical role in CVDs. Along with environmental factors, multiple studies reported that genetic factors affect RAS activity. Among a wide variety of RASrelated gene polymorphisms, insertion/deletion (I/D) polymorphism of ACE has been most extensively investigated. A recent systematic review, including 34,993 patients in 40 studies, suggested that the ACE D allele was significantly associated with an increased risk of myocardial infarction, especially in the Chinese population 1) . However, the association of ACE D allele with the risk of myocardial infarction remains controversial because publication bias overestimated its risk. Some studies identified ACE I/D as a modifier of CVD risk factors, including age 2) , smoking 2) , and hypertension 3) , although not as a prognostic predictor. In the Hisayama Study, a prospective cohort study in Japan 4) , Kondo et al. reported an interesting effect modification between ACE I/D and hypercholesterolemia in predicting the incidence of coronary heart disease (CHD). During the mean observational period of 16.2 years, 161 (7.6%) participants developed CHD. ACE I/D was never associated with CHD in Cox proportional hazards models. However, ACE I/ D modified an association between baseline hypercholesterolemia defined as ≥ 220 mg/dL and the incidence of CHD. In subjects with ACE and ID, hypercholesterolemia was significantly associated with the incidence of CVD (multivariate-adjusted hazard ratio 1.53 [95% confidence interval (CI) 1.06 2.20]). Their association was remarkably enhanced in subject with ACE DD (4.02 [1.79 9.02], P for interaction 0.03). The authors also showed that the serum total cholesterol level as a continuous variable provided a similar effect modification.
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The results of the Hisayama Study were contrary to a previous French case-control study, the Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) study, including 610 male patients with myocardial infarction and 733 controls 5) . The main exposure of interest was a composite of hyperlipidemia and/or obesity defined as plasma ApoB levels ≥ 125 mg/dL (the approximate median value in controls), use of lipid-lowering drugs, and/or a body mass index ≥ 26 kg/m 2 (the approximate median value in controls). Subjects with hyperlipidemia and/or obesity were at significantly higher risk of myocardial infarction among subjects with ACE /ID (crude odds ratio 3.33 [95%CI 2.29 4.84], calculated from the result), but not among those with ACE DD (1.25 [0.77 2.03]). A significant effect modification was observed even after adjusting for clinically relevant covariates (P for interaction 0.02). The authors claimed that sensitivity analyses by using serum total cholesterol or lowdensity lipoprotein cholesterol (LDL-C) level also showed similar results.
Although both studies reported that ACE I/D modified an association between hypercholesterolemia and CVD, their findings were contrasting. Considering the study design, larger sample size, longer observational period, strict definition of the exposure variable, and statistical models adjusting for clinically relevant factors more carefully, the Hisayama study might provide less biased, more persuasive results. Nevertheless, the findings need further investigations, in addition to replication of the results in different cohorts. First, biologically plausible mechanisms of an association between ACE I/D and hyperlipidemia should be identified in experimental studies. Kondo et al. suggested a link between ACE I/D-dependent ACE the ACE I/D predicted cholesterol-lowering effect of fluvastatin as described above, no significant difference in CVD incidence was observed among the patients with ACE , ID, and DD 6) . Two other randomized controlled trials, the Cholesterol And Recurrent Events (CARE) study 8) and the Genetics of Hypertension-Associated Treatment (GenHAT) study 9) did not find a significant difference in the incidence of CVDs among subjects with ACE I/D. Conversely, a Dutch cohort study of the general population, the Rotterdam study, reported a significant interaction between ACE I/D and the use of statins (synergy index for ACE DD vs. , 7.41 [95%CI 1.17 46.8]) 10) . The incidence of CHD was extremely, though not significantly, lowered by the use of statins in male subjects with ACE (statin user vs. non-user, multivariate-adjusted hazard ratio 0. enzymatic activity and LDL-C peroxidation. Their interesting hypothesis should be examined in vitro and in vivo. Second, because hypercholesterolemia is now regarded as one of the critical therapeutic targets to prevent CVD by using cholesterol-lowering drugs, mainly statins, the predictive power of ACE I/D in the cardiovascular protective response to these drugs have a greater clinical impact. One of the great disadvantages of these studies was a lack of information on the use of cholesterol-lowering drugs during the follow-up period.
Two studies reported inconsistent findings of an association between ACE I/D and the cholesterol-lowering effect of statin ( Table 1) . A randomized placebocontrolled trial, the Lipoprotein and Coronary Atherosclerosis Study (LCAS) enrolling 364 patients with coronary arterial stenosis, showed that the patients with ACE DD, as compared to those with ACE and ID, had a greater reduction in serum total cholesterol and low density lipoprotein cholesterol (LDL-C) levels after receiving fluvastatin, whereas not after receiving a placebo (P for interaction 0.018 and 0.005, respectively) 6) . In contrast, a small Greek cohort study including 49 patients with familial hypercholesterolemia reported no difference in the decrease in serum LDL-C levels after 12 weeks of atorvastatin therapy 7) . Remarkable differences in the clinical background of the patients between two studies might be the reason for their contradictory findings.
An association between ACE I/D and the cardiovascular protective effect of statins was assessed in several studies ( Table 2) . Although the LCAS reported 
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